Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Compensated Liver Cirrhosis
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Open-label, single arm, multicenter phase II trial assessing the tolerability of a reduced
starting dose of 40 mg cabozantinib for 4 weeks and subsequent dose escalation to 60 mg
cabozantinib until disease progression or intolerable toxicities.
Phase:
Phase 2
Details
Lead Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest